In PCa, genetic changes in the androgen receptor (AR), such as point mutation and gene amplification, render the receptor independent of upstream testosterone levels and cause resistance against androgen deprivation therapy (ADT), which is the predominant first line therapy for advanced disease [9]. Here, AR is linked to posterior cortical atrophy.